Hemab Therapeutics Revenue and Competitors

Copenhagen,

Location

#3621

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Hemab Therapeutics's estimated annual revenue is currently $7.9M per year.(i)
  • Hemab Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Hemab Therapeutics has 51 Employees.(i)
  • Hemab Therapeutics grew their employee count by 96% last year.

Hemab Therapeutics's People

NameTitleEmail/Phone
1
Director Medical Affairs and Global External EngagementReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Hemab Therapeutics?

Hemab ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.

keywords:N/A

N/A

Total Funding

51

Number of Employees

$7.9M

Revenue (est)

96%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Hemab Therapeutics News

2022-04-06 - Abata Announces Formation of Advisory Board Comprised of ...

Maraganore serves as the chair of Hemab Therapeutics and as a director of Agios Pharmaceuticals, Beam Therapeutics, and Kymera Therapeutics. He...

2022-03-30 - Ken Frazier Joins Board of Eikon, which is Looking Like ...

He has taken board positions at Hemab Therapeutics, Kymera Therapeutics and Rain Therapeutics. Maraganore has also been tapped to serve as a...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$10.5M5237%N/A
#2
$6.3M54-30%N/A
#3
$7M54-5%N/A
#4
N/A542%N/A
#5
$14.1M5493%N/A